Medicinal Chemistry Research Technologies, Therapeutic Discovery, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
Bioorg Med Chem Lett. 2013 Apr 1;23(7):2056-60. doi: 10.1016/j.bmcl.2013.02.007. Epub 2013 Feb 13.
Cdc7 kinase is responsible for the initiation and regulation of DNA replication and has been proposed as a target for cancer therapy. We have identified a class of Cdc7 inhibitors based on a substituted indole core. Synthesis of focused indole and azaindole analogs yielded potent and selective 5-azaindole Cdc7 inhibitors with improved intrinsic metabolic stability (ie 36). In parallel, quantum mechanical conformational analysis helped to rationalize SAR observations, led to a proposal of the preferred binding conformation in the absence of co-crystallography data, and allowed the design of 7-azaindole 37 as a second lead in this series.
Cdc7 激酶负责 DNA 复制的起始和调控,已被提议作为癌症治疗的靶点。我们已经基于取代的吲哚核心鉴定了一类 Cdc7 抑制剂。对重点吲哚和氮杂吲哚类似物的合成产生了具有改进的内在代谢稳定性的有效且选择性的 5-氮杂吲哚 Cdc7 抑制剂(即 36)。同时,量子力学构象分析有助于合理化 SAR 观察结果,提出了在没有共结晶学数据的情况下的首选结合构象,并允许设计 7-氮杂吲哚 37 作为该系列的第二个先导化合物。